.jetcityimage/iStock Content through Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its leading biopharma choice for 2025 and measured one more nine labels in the space as obese. The expenditure financial institution stated in a keep in mind that it continues to believe “diabesity is actually readied to end up being.